Literature DB >> 19000329

Therapeutic and prophylactic applications of alphavirus vectors.

Gregory J Atkins1, Marina N Fleeton, Brian J Sheahan.   

Abstract

Alphavirus vectors are high-level, transient expression vectors for therapeutic and prophylactic use. These positive-stranded RNA vectors, derived from Semliki Forest virus, Sindbis virus and Venezuelan equine encephalitis virus, multiply and are expressed in the cytoplasm of most vertebrate cells, including human cells. Part of the genome encoding the structural protein genes, which is amplified during a normal infection, is replaced by a transgene. Three types of vector have been developed: virus-like particles, layered DNA-RNA vectors and replication-competent vectors. Virus-like particles contain replicon RNA that is defective since it contains a cloned gene in place of the structural protein genes, and thus are able to undergo only one cycle of expression. They are produced by transfection of vector RNA, and helper RNAs encoding the structural proteins. Layered DNA-RNA vectors express the Semliki Forest virus replicon from a cDNA copy via a cytomegalovirus promoter. Replication-competent vectors contain a transgene in addition to the structural protein genes. Alphavirus vectors are used for three main applications: vaccine construction, therapy of central nervous system disease, and cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19000329     DOI: 10.1017/S1462399408000859

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN: 1462-3994            Impact factor:   5.600


  33 in total

1.  In vitro and in vivo characterization of microRNA-targeted alphavirus replicon and helper RNAs.

Authors:  Kurt I Kamrud; V McNeil Coffield; Gary Owens; Christin Goodman; Kim Alterson; Max Custer; Michael A Murphy; Whitney Lewis; Sarah Timberlake; Elizabeth K Wansley; Peter Berglund; Jonathan Smith
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

Review 2.  Vaccines: the fourth century.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2009-09-30

3.  CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes.

Authors:  Sandra Lazzaro; Cinzia Giovani; Simona Mangiavacchi; Diletta Magini; Domenico Maione; Barbara Baudner; Andrew J Geall; Ennio De Gregorio; Ugo D'Oro; Cecilia Buonsanti
Journal:  Immunology       Date:  2015-08-28       Impact factor: 7.397

Review 4.  mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

Authors:  Giulietta Maruggi; Cuiling Zhang; Junwei Li; Jeffrey B Ulmer; Dong Yu
Journal:  Mol Ther       Date:  2019-02-07       Impact factor: 11.454

5.  Nonviral delivery of self-amplifying RNA vaccines.

Authors:  Andrew J Geall; Ayush Verma; Gillis R Otten; Christine A Shaw; Armin Hekele; Kaustuv Banerjee; Yen Cu; Clayton W Beard; Luis A Brito; Thomas Krucker; Derek T O'Hagan; Manmohan Singh; Peter W Mason; Nicholas M Valiante; Philip R Dormitzer; Susan W Barnett; Rino Rappuoli; Jeffrey B Ulmer; Christian W Mandl
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

6.  A cationic nanoemulsion for the delivery of next-generation RNA vaccines.

Authors:  Luis A Brito; Michelle Chan; Christine A Shaw; Armin Hekele; Thomas Carsillo; Mary Schaefer; Jacob Archer; Anja Seubert; Gillis R Otten; Clayton W Beard; Antu K Dey; Anders Lilja; Nicholas M Valiante; Peter W Mason; Christian W Mandl; Susan W Barnett; Philip R Dormitzer; Jeffrey B Ulmer; Manmohan Singh; Derek T O'Hagan; Andrew J Geall
Journal:  Mol Ther       Date:  2014-07-16       Impact factor: 11.454

7.  Genome-wide RNAi screen identifies SEC61A and VCP as conserved regulators of Sindbis virus entry.

Authors:  Debasis Panda; Patrick P Rose; Sheri L Hanna; Beth Gold; Kaycie C Hopkins; Randolph B Lyde; Michael S Marks; Sara Cherry
Journal:  Cell Rep       Date:  2013-12-12       Impact factor: 9.423

8.  Rubella virus-like replicon particles: analysis of encapsidation determinants and non-structural roles of capsid protein in early post-entry replication.

Authors:  Claudia Claus; Wen-Pin Tzeng; U G Liebert; Teryl K Frey
Journal:  J Gen Virol       Date:  2011-11-23       Impact factor: 3.891

Review 9.  Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.

Authors:  Barney S Graham
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

10.  Development and characterization of promoterless helper RNAs for the production of alphavirus replicon particle.

Authors:  K I Kamrud; K Alterson; M Custer; J Dudek; C Goodman; G Owens; J F Smith
Journal:  J Gen Virol       Date:  2010-02-24       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.